Raymond James on Relay (RLAY): ' ~60% upside to Relay’s current stock price, and we think with further derisking for a 1L breast cancer study that is conservative'
Tweet Send to a Friend
Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Relay Therapeutics (NASDAQ: RLAY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
